Transactions: Licensing, Investment, and Partnerships Photo by Antonella Vilardo on Unsplash Cinda Biopharmaceuticals enters ADC On June 29, Cinda announced the signing of a non-exclusive, target-specific licensing agreement with Synaffix B.V. Synaffix will provide...
The Shanghai Stock Exchange and Technology Innovation Board (STAR Market) recently celebrated its second anniversary. The past two years have been busy ones. As of June 2, 2021, a total of 517 companies had applied for registration with STAR Market, of which 314 were...
The presence of robotic surgery has brought a lot of change to the OR. Compared with traditional surgery methods, robotic surgery can have such advantages as being less invasive and having higher precision, less blood, less scarring, reduced infection rates, and a...
On March 17 of this year, the Chinese National Medical Products Administration (NMPA) approved the registration application for the innovative product “Disposable Electronic Ureteral Endoscopic Catheter” produced by Beijing Beifang Tengda Technology...
According to research from MyBioGate, in April, the global pharmaceutical industry reached at least 23 transactions, mainly mergers and acquisitions and licensing. M&A transactions mainly occurred between non-Chinese pharmaceutical companies. Two M&As were...
New drug approval: Telitacicept On March 12, the State Food and Drug Administration in China issued an announcement, authorizing conditional approval for RemeGen’s therapeutic biological product for injection, Telitacicept. The drug is an innovative drug TACl-Fc...
Recent Comments